On 14 May 2019, the FDA approved avelumab in combination with axitinib (Inlyta) for the first-line treatment of patients with advanced RCC and it is the first FDA approval for an anti-PD-L1 therapy as part of a combination regimen for patients with advanced RCC. The gene discussed is CD274; the disease is renal cell adenocarcinoma.